PATENT CLAIM ANALYSIS

Application Number: 15778368
Application Type: Utility
Filing Date: 2018-05
Publication Date: 2018-11
Patent Classification: ["424", "218100"]

Abstract:
A highly safe dengue vaccine was invented that induced a neutralizing antibody response against all of the four serotypes of dengue virus without developing more than a fixed level of viremia with single administration. A tetravalent dengue virus formulation is provided that is excellent in both efficacy (neutralizing antibody response) and safety (viremia).

Claim (Index 43):
A process for preparing the attenuated serotype 1 dengue virus of any one of  claims 1  to  9 , which comprises subjecting serotype 1 dengue virus parent strain 03135 having an amino acid sequence of SEQ ID NO: 1 as analyzed using a Next Generation Sequencer to 15 to 25 passage cultures in primary dog kidney (PDK) cells to obtain an attenuated strain, and further subjecting said attenuated strain to passage culture in African green monkey kidney (Vero) cells.

Metadata:
- Claim Count in Document: 11.0
- Percentile: 93.0
- Lexical Diversity: 1.37209
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['15195820', '11449876', '11453344', '13212845', '13281240']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7425021430923219
- 35 USC 102 Novelty (BERT): 0.5434688895597863
- Combined Prediction Score: 0.7225988177390683
- Mean Citation Score: 370.044854
- Max Citation Score: 379.45105
- Similarity Product: 240.1273610950619

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test